Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

February 8, 2021 updated by: Julia M. Esparza, Louisiana State University Health Sciences Center Shreveport

This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection.

The research is focused on these questions:

Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection.

The research is focused on these questions:

Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?

Study Type

Observational

Enrollment (Actual)

386

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Louisiana
      • Shreveport, Louisiana, United States, 71103
        • Louisiana State University Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Northern Louisiana community members in the Ambulatory Care Clinics in University Health.

Northern Louisiana, Louisiana State University Health, clinical faculty, residents and medical students.

Description

Community Participants

Inclusion

All visitors to the Pediatric or Internal Medicine University Health Shreveport Clinics willing to complete a survey

Community Study Exclusion

Those do not wish to participate in the study

Those who English is not their first language

Clinical Faculty, Resident, and Medical Student Study

Inclusion

All Louisiana State University Shreveport Health Clinical Faculty, Resident, and Medical Student Inclusion willing to to complete the online survey.

Clinical Faculty, Resident, and Medical Student Study

Exclusion

Any LSU Health Shreveport Clinical Faculty, Resident, and Medical Student which declines to take the survey or do not attempt to complete it.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Community Group Survey
Community members coming into the University Health Shreveport Ambulatory Care Facility.
Other: Survey
Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
Physician Group Survey
Physicians affiliated with LSU Health Shreveport School of Medicine
Other: Survey
Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Barriers to HPV Vaccination
Time Frame: 60 days
What are the barriers which prevent community members and physicians, residents and medical students from ensuring that males age 9-26 are vaccinated with the HPV three-shot vaccination.
60 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knowledge pertaining to ease of Human Papillomavirus transmission.
Time Frame: 60 days
Do community members and physicians understand the ease of HPV transmission?
60 days
Knowledge of Associated HPV diseases
Time Frame: 60 days
Do community member and physicians know the associated HPV diseases?
60 days
Knowledge of age in which males should be vaccinated against HPV.
Time Frame: 60 days
Do community member and physicians know the age in which males should be vaccinated against HPV?
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Louisiana State University Health Sciences Center Shreveport

Investigators

  • Principal Investigator: Julia M Esparza, MLS, 3186754179

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2016

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

April 1, 2020

Study Registration Dates

First Submitted

September 7, 2016

First Submitted That Met QC Criteria

September 7, 2016

First Posted (Estimate)

September 13, 2016

Study Record Updates

Last Update Posted (Actual)

February 10, 2021

Last Update Submitted That Met QC Criteria

February 8, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00000618

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Only aggregate data will be shared.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Papillomavirus Infections

Clinical Trials on Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe